Methyclothiazide
Aquatensen, Diutensen-r, Enduron, Enduronyl, Eutron (methyclothiazide) is a small molecule pharmaceutical. Methyclothiazide was first approved as Enduronyl on 1982-01-01. It is used to treat edema, glomerulonephritis, heart failure, hypertension, and liver cirrhosis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methyclothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ENDURON | AbbVie | N-012524 DISCN | 1982-01-01 | 2 products, RLD |
| AQUATENSEN | Medpointe Pharm Hlc | N-017364 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Methyclothiazide
+
Reserpine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DIUTENSEN-R | Medpointe Pharm Hlc | N-012708 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Deserpidine
+
Methyclothiazide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ENDURONYL | Abbott Biotherapeutics | N-012775 DISCN | 1982-01-01 | 1 products |
| ENDURONYL FORTE | Abbott Biotherapeutics | N-012775 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Methyclothiazide
+
Pargyline hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EUTRON | Abbott Biotherapeutics | N-016047 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | — | — | 2 | 3 | 5 |
| Rheumatic diseases | D012216 | — | M79.0 | — | — | — | 2 | 2 | 4 |
| Collagen diseases | D003095 | — | — | — | — | — | 2 | 2 | 4 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | 1 | 2 | 3 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | 2 | — | 2 |
| Femoral fractures | D005264 | — | S72 | — | — | — | 2 | — | 2 |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | 2 | — | 2 |
| Congenital hip dislocation | D006618 | — | Q65.2 | — | — | — | 2 | — | 2 |
| Hip dislocation | D006617 | — | S73.00 | — | — | — | 2 | — | 2 |
| Necrosis | D009336 | — | — | — | — | — | 2 | — | 2 |
Show 3 more
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Joint diseases | D007592 | — | M12.9 | — | — | — | — | 2 | 2 |
| Musculoskeletal diseases | D009140 | — | — | — | — | — | — | 2 | 2 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methyclothiazide |
| INN | methyclothiazide |
| Description | Methyclothiazide is a benzothiadiazine. |
| Classification | Small molecule |
| Drug class | diuretics (thiazide derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN1C(CCl)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O |
Identifiers
| PDB | — |
| CAS-ID | 135-07-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1577 |
| ChEBI ID | 6847 |
| PubChem CID | 4121 |
| DrugBank | DB00232 |
| UNII ID | L3H46UAC61 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Methyclothiazide
+
Deserpidine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Methyclothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 225 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use